Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
Oncolytics Biotech Inc. announced that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
"Interim data recently presented from our U.K. Phase I dose escalation trial of REOLYSIN(R) in combination with paclitaxel and carboplatin indicated strong and durable responses in patients with advanced head and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics. "We believe it is important to further explore these findings by conducting a Phase II trial in this specific patient population."
This trial is a 14 patient, single arm, open-label, dose-targeted, non-randomized, multi-centre trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Patients with a variety of advanced cancers, including head and neck cancers, will continue to be treated in the ongoing U.K. combination paclitaxel and carboplatin trial.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
List_of_Filistatidae_species
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well
Model may offer better understanding of embryonic development

Regenerative therapies for previously incurable muscle diseases - Million euro support for MyoPax
Molecularly shutting down cancer cachexia

Reusable plastic bottles release hundreds of chemicals - Have you ever experienced the strange taste of water after it has been in a reusable plastic bottle for a while?
List_of_Dipluridae_species
